Some examples of therapies based on PD genetic determinants that have been developed in preclinical models and are currently in clinical trials include strategies to counter the aggregation of alpha-synuclein, encoded by the SNCA gene1, or to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2)2. This evidence concerns the gene LRRK2 and Parkinson disease.